Most companies that have gone public this year are biotech firms and the first quarter marked the slowest start to IPOs since the last recession. In the current quarter, [could] the fact that companies outside of biotech are eyeing or marching through the IPO door… be a sign of a slow thaw?
Written by MotifInvesting.com
Last month, Bats Global Inc. (BATS: BATS) raised $253 million in an initial offering that valued the company at $1.8 billion. Bats increased the deal’s size after demand for shares exceeded the 11.2 million originally offered by 20 times. After a mere dribble of initial public offerings in this year’s first quarter, the idea that one new issue priced its shares above its asking range then surged 20% in its first day of trading was welcome news for investors looking for a sign that the IPO market has started to thaw.
Bats shares closed Monday at $25.97, well above the stock’s $19 IPO price, helped by its first quarterly earnings report last week as a public company. It posted record first-quarter profit thanks to higher market volume and growing market share.2
IPO market a mixed bag so far
…Not every IPO has panned out as well as Bats, [however].
Leave A Comment